AI English summary of an SEC filing — figures as filed
Universal Health Services UHSThe company said net revenues for Q3 2025 increased 13.4% from $3.963 billion a year earlier to $4.495 billion. Net income attributable to UHS was $373.0 million ($5.86 per diluted share), compared with $258.7 million ($3.80 per share) a year earlier.
Key points
AI summaryThe company said net revenues for Q3 2025 increased 13.4% from $3.963 billion a year earlier to $4.495 billion. Net income attributable to UHS was $373.0 million ($5.86 per diluted share), compared with $258.7 million ($3.80 per share) a year earlier.
The company said Q3 2025 results included items that were not in the forecast it had disclosed on July 28. These were pre-tax reimbursements of $90 million (net of related provider taxes) under a Medicaid state directed payment program in Washington, D.C., and a pre-tax charge of $35 million to increase reserves for self-insured professional and general liabilities.
The company said it expects full-year 2025 net revenues of $17.306 billion to $17.445 billion, Adjusted EBITDA net of NCI of $2.569 billion to $2.619 billion, and Adjusted EPS of $21.50 to $22.10 per share. Its previous outlook was $17.096 billion to $17.312 billion, $2.458 billion to $2.543 billion, and $20.00 to $21.00 per share.
The company said its board of directors on October 27, 2025 increased the stock repurchase program authorization by $1.5 billion, and that the current remaining repurchase authorization, including the increase, is $1.759 billion. It said it repurchased 3.190 million shares at an aggregate cost of approximately $565.8 million during the first 9 months of 2025.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Q3 2025 net revenues $4.495 billion
The company said net revenues for Q3 2025 increased 13.4% from $3.963 billion a year earlier to $4.495 billion. Net income attributable to UHS was $373.0 million ($5.86 per diluted share), compared with $258.7 million ($3.80 per share) a year earlier.
Source · Based on the filing body and exhibits
Washington, D.C. reimbursements and reserves not in Q3 outlook
The company said Q3 2025 results included items that were not in the forecast it had disclosed on July 28. These were pre-tax reimbursements of $90 million (net of related provider taxes) under a Medicaid state directed payment program in Washington, D.C., and a pre-tax charge of $35 million to increase reserves for self-insured professional and general liabilities.
Source · Based on the filing body and exhibits
Full-year 2025 outlook range changed
The company said it expects full-year 2025 net revenues of $17.306 billion to $17.445 billion, Adjusted EBITDA net of NCI of $2.569 billion to $2.619 billion, and Adjusted EPS of $21.50 to $22.10 per share. Its previous outlook was $17.096 billion to $17.312 billion, $2.458 billion to $2.543 billion, and $20.00 to $21.00 per share.
Source · Based on the filing body and exhibits
Stock repurchase authorization raised by $1.5 billion
The company said its board of directors on October 27, 2025 increased the stock repurchase program authorization by $1.5 billion, and that the current remaining repurchase authorization, including the increase, is $1.759 billion. It said it repurchased 3.190 million shares at an aggregate cost of approximately $565.8 million during the first 9 months of 2025.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…